We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+48.28%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$392M
AUM Growth
+$42.8M
Cap. Flow
-$39.5M
Cap. Flow %
-10.09%
Top 10 Hldgs %
70.95%
Holding
53
New
14
Increased
7
Reduced
6
Closed
18

Top Buys

Rank Stock Value
1
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$20.9M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$14.5M
3
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$12.9M
4
ADMS
Adamas Pharmaceuticals
ADMS
+$7.48M
5
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$5.91M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$25M
2
BLUE
bluebird bio
BLUE
+$21.6M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$21.3M
4
XNCR icon
Xencor
XNCR
+$8.55M
5
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$7.4M

Sector Composition

Rank Sector Weight
1 Healthcare 77.25%
2 Technology 1.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
1
Vanda Pharmaceuticals
VNDA
$307M
$45M 11.49%
2,706,134
+376
+0% +$5.06K
ADMS
2
DELISTED
Adamas Pharmaceuticals
ADMS
$42.7M 10.89%
2,601,351
+492,252
+23% +$7.48M
SGYP
3
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$35.4M 9.03%
6,422,232
-1,167,768
-15% -$5.47M
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$27.9M 7.12%
2,440,959
– –
FOMX
5
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$25.6M 6.54%
2,769,425
+2,494,669
+908% +$20.9M
DERM
6
DELISTED
Dermira, Inc.
DERM
$23M 5.86%
679,403
-120,597
-15% -$3.88M
RXDX
7
DELISTED
Ignyta, Inc.
RXDX
$21.9M 5.58%
3,475,227
+236,524
+7% +$1.37M
ENTA icon
8
Enanta Pharmaceuticals
ENTA
$366M
$21M 5.36%
790,000
+251,976
+47% +$5.85M
NBIX icon
9
Neurocrine Biosciences
NBIX
$16.8B
$20M 5.09%
394,080
-75,920
-16% -$3.78M
AVXS
10
DELISTED
AveXis, Inc. Common Stock
AVXS
$15.7M 4.01%
+381,095
New +$14.5M
MACK
11
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$15.5M 3.96%
+310,398
New +$12.9M
CLCD
12
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$15.3M 3.89%
+400,000
New +$5.91M
APYX icon
13
Apyx Medical
APYX
$173M
$14M 3.56%
2,680,000
– –
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$12.2M 3.11%
264,893
-65,107
-20% -$2.65M
CNXR
15
DELISTED
Connecture, Inc.
CNXR
$7.76M 1.98%
4,127,232
– –
ARDM
16
DELISTED
Aradigm Corp Common Stock
ARDM
$6.9M 1.76%
1,002,962
– –
OCRX
17
DELISTED
Ocera Therapeutics, Inc.
OCRX
$5.18M 1.32%
1,963,777
– –
DBVT
18
DBV Technologies
DBVT
$799M
$4.78M 1.22%
+13,145
New +$4.57M
VIRX
19
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.65M 1.19%
30,388
-8,536
-22% -$1.2M
ALIM
20
DELISTED
Alimera Sciences
ALIM
$3.93M 1%
+175,865
New +$4.05M
BCRX icon
21
PUT
BioCryst Pharmaceuticals
BCRX
$2.28B
$3.2M 0.82%
+725,000
New +$2.9M
GWPH
22
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.16M 0.81%
+23,800
New +$2.27M
PLXP
23
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$2.59M 0.66%
22,366
+11,377
+104% +$1.11M
TENX icon
24
Tenax Therapeutics
TENX
$363M
$2.57M 0.66%
35
– –
PDLI
25
DELISTED
PDL BioPharma, Inc.
PDLI
$2.16M 0.55%
+645,000
New +$2.05M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2016 Portfolio in Review

As of Q3 2016, Great Point Partners held 53 positions worth $392M, up 12% from $349M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Great Point Partners withdrew a net $39.5M in Q3 2016, closing 18 positions and reducing 6 holdings. Its most notable exit was Exelixis, an estimated $25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 74% a quarter earlier, followed by Technology.

Against the trend, Great Point Partners opened a new position in AveXis, Inc. Common Stock worth $15.7M.

  • Great Point Partners's largest Q3 2016 buy was AveXis, Inc. Common Stock: 381,095 shares worth $15.7M.
  • Great Point Partners added most to Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2016, an estimated $20.9M increase.
  • Great Point Partners's biggest Q3 2016 reduction was Tetraphase Pharmaceuticals, Inc., cutting an estimated $7.4M.
  • Great Point Partners fully exited Exelixis in Q3 2016, selling an estimated $25M.
  • Great Point Partners's ten largest holdings make up 71% of its $392M portfolio in Q3 2016.
  • Great Point Partners opened 14 new positions and closed 18 in Q3 2016.
  • Great Point Partners's portfolio value rose 12% quarter-over-quarter to $392M.

Based on Great Point Partners's 13F filing for Q3 2016, filed 14 Nov 2016.